Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.
In November 2015, the CALYM Carnot Institute held a 2-d workshop to discuss the current and future development of immunomodulatory antibodies for the treatment of lymphoma. Highlights from the workshop are presented in this article.
Department of Hematology, CHU de Rennes , Rennes, France.
Roch
R
Houot
Department of Pathology, Inserm U955, Université Paris-Est, CHU Henri Mondor , Créteil, France.
Philippe
P
Gaulard
Department of Pathology and Immunology, Washington University , St. Louis, MO, USA.
Robert
R
Schreiber
Genentech , South San Francisco, CA, USA.
Ira
I
Mellman
Department of Clinical Immunology and Internal Medicine, Hospital Kremlin Bicêtre, Université Paris-Sud , Orsay, France.
Olivier
O
Lambotte
de Duve Institute, Université Catholique de Louvain , Brussels, Belgium.
Pierre G
PG
Coulie
Inserm U917, CHU de Rennes , Rennes, France.
Thierry
T
Fest
Bristol-Myers Squibb , CA, USA.
Alan
A
Korman
Stanford School of Medicine , Stanford, CA, USA.
Ronald
R
Levy
Dana-Farber Cancer Institute , Boston, MA, USA.
Margaret
M
Shipp
Inserm U917, CHU de Rennes , Rennes, France.
Karin
K
Tarte
Department of Medicine, Stanford School of Medicine , Stanford, CA, USA.
Holbrook
H
Kohrt
Gustave Roussy Cancer Campus , Villejuif, France.
Aurélien
A
Marabelle
Division of Hematology , Mayo Clinic, Rochester, MN, USA.
Stephen
S
Ansell
CHRU de Tours, Université François-Rabelais and CNRS, UMR7292 , Tours, France.
Hervé
H
Watier
Aduro Biotech Europe , Oss, The Netherlands.
Andrea
A
van Elsas
Clinical Research-Oncology , Merck & Co , Kenilworth, NJ, USA.
Arun
A
Balakumaran
UCL Cancer Institute, University College of London , London, UK.
Frederick
F
Arce Vargas
UCL Cancer Institute, University College of London , London, UK.
Sergio A
SA
Quezada
Department of Hematology, Université Claude Bernard, Hospices Civils de Lyon , INSERM 1052 , Lyon, France.
Gilles
G
Salles
Inserm UMR 1068, Institut Paoli Calmettes, Aix Marseille Université , Marseille, France.
Daniel
D
Olive
Immunomodulation; immunotherapy; lymphoma; programmed cell death 1 ligand 1; programmed cell death 1 receptor